Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Mol Cancer Ther (2024) 23 (5): 662–671.

https://doi.org/10.1158/1535-7163.MCT-23-0552

Published: 02 May 2024

View article titled, Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Includes: Supplementary data

Journal Articles

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Wenjuan Zhang, Rachael A. Vaubel, Ju-Hee Oh, Ann C. Mladek, Surabhi Talele, Wenqiu Zhang, Katie L. Waller, Danielle M. Burgenske, Jann N. Sarkaria, William F. Elmquist

Mol Cancer Ther (2024) 23 (1): 47–55.

https://doi.org/10.1158/1535-7163.MCT-23-0217

Published: 03 January 2024

View article titled, Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Includes: Supplementary data

Journal Articles

Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts

Zhiyi Xue, Ann C. Mladek, Sneha Rathi, Danielle M. Burgenske, Shiv K. Gupta, Brett L. Carlson, Zeng Hu, Lauren L Ott, Katrina K. Bakken, Rachael A. Vaubel, William F Elmquist, Wei Zhong, Jann N Sarkaria

Mol Cancer Ther (2023) 22 (12_Supplement): A148.

https://doi.org/10.1158/1535-7163.TARG-23-A148

Published: 01 December 2023

View article titled, Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts

Journal Articles

Abstract A002: The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies

Danielle M Burgenske, Ann C Mladek, Katrina K Bakken, Zeng Hu, Brett L Carlson, Paul A Decker, Jeanette E Eckel-Passow, Jann N Sarkaria

Mol Cancer Ther (2023) 22 (12_Supplement): A002.

https://doi.org/10.1158/1535-7163.TARG-23-A002

Published: 01 December 2023

View article titled, Abstract A002: The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies

Journal Articles

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Sani H. Kizilbash, Shiv K. Gupta, Karen E. Parrish, Janice K. Laramy, Minjee Kim, Gautham Gampa, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, William F. Elmquist, Jann N. Sarkaria

Mol Cancer Ther (2021) 20 (6): 1009–1018.

https://doi.org/10.1158/1535-7163.MCT-20-0640

Published: 01 June 2021

View article titled, In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Includes: Supplementary data

Journal Articles

Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models

Ann C Mladek, Shiv Gupta, Minjee Kim, Afroz Shareef Mohammad, Katrina K Bakken, Helen He, Zeng Hu, Danielle M Burgenske, Brett L Carlson, William F Elmquist, Jann Sarkaria

Mol Cancer Ther (2019) 18 (12_Supplement): C051.

https://doi.org/10.1158/1535-7163.TARG-19-C051

Published: 01 December 2019

View article titled, Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models

Journal Articles

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Danielle M Burgenske, Ann C Mladek, Jenny L Pokorny, Heidi A Lane, Felix Bachmann, Rachael A Vaubel, Mark A Schroeder, Katrina K Bakken, Lihong He, Zeng Hu, Brett L Carlson, Surabhi Talele, Gautham Gampa, Matthew L Kosel, Paul A Decker, Jeanette E Eckel-Passow, William F Elmquist, Jann Sarkaria

Mol Cancer Ther (2019) 18 (12_Supplement): C096.

https://doi.org/10.1158/1535-7163.TARG-19-C096

Published: 01 December 2019

View article titled, Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Journal Articles

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Mol Cancer Ther (2018) 17 (9): 1893–1901.

https://doi.org/10.1158/1535-7163.MCT-17-0600

Published: 04 September 2018

View article titled, Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Includes: Supplementary data

Journal Articles

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Sani H. Kizilbash, Shiv K. Gupta, Kenneth Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria

Mol Cancer Ther (2017) 16 (12): 2735–2746.

https://doi.org/10.1158/1535-7163.MCT-17-0365

Published: 03 December 2017

View article titled, Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Includes: Supplementary data

Journal Articles

Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Yulian P. Ramirez, Ann C. Mladek, Roger M. Phillips, Mikko Gynther, Jarkko Rautio, Alonzo H. Ross, Richard T. Wheelhouse, Jann N. Sakaria

Mol Cancer Ther (2015) 14 (1): 111–119.

https://doi.org/10.1158/1535-7163.MCT-14-0113

Published: 13 January 2015

View article titled, Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Includes: Supplementary data

Journal Articles

Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.

Ryan S. Youland, Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jann N. Sarkaria

Mol Cancer Ther (2011) 10 (11_Supplement): B68.

https://doi.org/10.1158/1535-7163.TARG-11-B68

Published: 12 November 2011

View article titled, Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.

Journal Articles

Abstract C191: The effect of the cyclin‐dependent kinase inhibitor PD 0332991 on glioblastoma cells and relationship with p15INK4B/p16INK4A expression

Ling Cen, Jamie L. Ostrem, Mark A. Schroeder, Ann C. Mladek, Stephanie R. Fink, Robert B. Jenkins, Jann N. Sarkaria

Mol Cancer Ther (2009) 8 (12_Supplement): C191.

https://doi.org/10.1158/1535-7163.TARG-09-C191

Published: 10 December 2009

View article titled, Abstract C191: The effect of the cyclin‐dependent kinase inhibitor PD 0332991 on glioblastoma cells and relationship with p15INK4B/p16INK4A expression

Journal Articles

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu, E. Ruth Plummer, Jann N. Sarkaria

Mol Cancer Ther (2009) 8 (2): 407–414.

https://doi.org/10.1158/1535-7163.MCT-08-0854

Published: 11 February 2009

View article titled, Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

NARROW

Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts

Abstract A002: The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.

Abstract C191: The effect of the cyclin‐dependent kinase inhibitor PD 0332991 on glioblastoma cells and relationship with p15INK4B/p16INK4A expression

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only